Crucell’s strong product portfolio is supported through a range of patented technologies. Our technologies open up new areas of research, speed our development programs and optimize production processes. Crucell continues to extend the applications of existing technologies, while simultaneously exploring novel technology platforms. Learn more

Our current product pipeline includes the following main areas:

Vaccines

• Classical Vaccines – Many viruses have been shown to grow extremely well on our PER.C6^® cells under controlled and scalable conditions. These viruses can then be inactivated, purified and marketed as inactivated whole virus (also called “whole-killed”), split or subunit vaccines.
• Recombinant Vaccines – Our adenovirus-based AdVac^® vectors can be used to create recombinant vaccines by inserting a small piece of genetic material from the disease causing virus into a harmless adenoviral vector that acts as a “vehicle”. The recombinant vaccine triggers an immune response in the vaccinated individual against the disease causing virus, thereby preventing or treating infection with the virus. The AdVac^®-based vaccine can subsequently be manufactured to large-scale commercial volumes on the PER.C6^® cell line.

Proteins

• Recombinant Proteins – Recombinant proteins, such as blood factors, can be produced efficiently and safely on the PER.C6^® cell line.

• Antibodies – MAbstract^® technology is used to identify strong binding and neutralizing antibodies for specific disease targets. Antibodies discovered in this way can then be produced on PER.C6^® technology.

Learn more about Crucell’s development programs

Products

Partners

Technology